Currently, Martin Babler occupies the position of Chairman, President & Chief Executive Officer at Alumis, Inc.

He is also on the board of Biotechnology Innovation Organization, Prelude Therapeutics, Inc., Neoleukin Therapeutics, Inc. and Omega Alpha SPAC.

In the past Mr. Babler occupied the position of President & Chief Executive Officer for Talima Therapeutics, Inc., Principal at Eli Lilly & Co., President, Chief Executive Officer & Director at Principia Biopharma, Inc. and Vice President-Immunology Sales & Marketing at Genentech, Inc.

He received an undergraduate degree from Swiss Federal Institute of Technology.